Clinical Trial Update: Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating recombinant Factor XIII (catridecacog) for prevention of bleeding in patients with Factor XIII deficiency was completed; results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Factor Xiii Deficiency

Drugs mentioned

• catridecacog (catridecacog)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2014-07-14